ABsTRACT Clinical remission has been the therapeutic goal of Crohn's disease treatment for many years. While it has helped to ameliorate the symptoms, this treatment strategy has not brought about significant changes in the need for abdominal surgery in the natural history of Crohn's disease. The advent of biological agents (biologics) has shown that it is possible to induce and maintain mucosal healing in a significant proportion of treated patients. Data is also emerging to show that this has translated to fewer instances of hospitalisation and surgery for these patients. This is a paradigm shift in the therapeutic goal of Crohn's disease treatment.
INTRODUCTION

INTesTINAl UlCeRs AND INfl AmmATION IN CROHN' s DIse Ase
Chronic intestinal inflammation causes GI ulcers in CD. This is a transmural inflammation. (1) The intact GI mucosa is a vital part of the mucosal barrier that separates the luminal microbiota from the mucosal immune system. In the intestines, components of the mucosal barrier include the intact epithelial cell layer, tight junctions, and antimicrobial peptides such as defensins, which are produced by the intestinal mucosa. Defects in different components of this barrier have been found in patients with inflammatory bowel disease (IBD). For example, it has been suggested that altered defensin production plays an important role in the pathogenesis of IBD. (2) Similarly, defects in proteins that make up the tight junctions, such as the occludins and claudins, have also been described in patients with IBD. These defects are believed to cause breaks in the mucosal barrier, which permit the passage of microorganisms into the mucosa and submucosa. There, the microorganisms meet and activate the mucosal immune system, causing chronic intestinal inflammation.
An altered mucosal immune response has also been shown in animal models and IBD patients. (3) (4) (5) A relative deficiency of immune suppressor cells (e.g. regulatory T cells) have been found in IBD patients. (6) Differences in the way antigen-presenting cells and effector T cells respond to bacterial stimuli have also been shown in IBD patients, compared to normal controls. (7) One way by which this is mediated is through differences in the way the pattern recognition receptor NOD2/CARD15 recognises microorganisms in IBD patients versus healthy controls. (8) The NOD2/CARD15 gene is the first IBD gene to be discovered.
THeR ApeUTIC eNDpOINTs fOR CROHN' s DIse Ase
The target of gastroenterologists in treating patients has not changed for many years. (9) Although endoscopic, histological and radiological proof is required before a diagnosis of IBD can be made, gastroenterologists often treat CD patients only to relieve symptoms and achieve biochemical remission. The aim is not to achieve complete healing of the ulcers. This, however, is not unique to routine clinical practice. For instance, clinical trials examining the efficacy of novel therapies make use of disease activity indices, such as the Crohn's disease activity index (CDAI), which measure clinical symptoms and not endoscopic disease activity.
Until the advent of infliximab in the 1990s, it was not uncommon to find significant ulcers in CD patients in clinical and biochemical remission after a course of steroids. Trials of biological agents since the 1990s have taught us that a proportion of patients in clinical and biochemical remission, as defined by CDAI, also achieve complete healing of mucosal ulcers. (10) The impressive images of ulcer healing in patients who had received only one dose of infliximab demonstrated that contrary to what was often seen in CD patients with steroid-induced remission, it was possible for a significant proportion of patients to achieve ulcer healing.
this is difficult to achieve even in patients on biological agents, it would be useful to define partial mucosal healing. Endoscopic Of all the CD endoscopic indices, the Rutgeerts score is the only postoperative endoscopic grading system that has been used to describe the severity of endoscopic recurrence at the ileocolic anastomosis and preanastomotic ileum post resection. (16) Scoring is based on the presence of ulcers, ileitis, nodularity and strictures.
Grading ranges from i0 to i4. Although the reproducibility of the Rutgeerts scale has not been prospectively validated, the severity of endoscopic lesions at one-year post operation has been demonstrated to be predictive of clinical recurrence.
Postoperative recurrence was initially defined as Rutgeerts score i1, but most clinical trials have used i2 as the cutoff to define endoscopic recurrence. In a recent study, the preexisting Rutgeerts endoscopic score was modified to incorporate a scoring system of colonic lesions after surgery. (17) 
ClINICAl sIgNIfICANCe Of mUCOsAl He AlINg
When contemplating the use of mucosal healing as a therapeutic goal, it is important for both the clinician and patient to consider whether the presence of ulcers can predict future disease activity and future need for hospitalisation or major abdominal surgery, as well as whether mucosal healing will modify the natural history of IBD. This is especially important in patients who have already undergone their first abdominal surgery.
Allez et al have shown that the presence of deep ulcerations in CD patients was a risk factor for penetrating complications and surgery. (19) Among patients with severe endoscopic lesions in their cohort, the probability of colectomy was 31%, 42%, and 62% at one, three and eight years, respectively, whereas in the absence of severe endoscopic lesions, the probability of colectomy was 6%, 8% and 18% at the same time points. A study of postoperative patients revealed that CDAI could discriminate between those with and without endoscopic recurrence in only 65% of cases, suggesting that CDAI alone was inadequate for the detection of postoperative recurrence of CD. use. (24) In the longer term, mucosal healing has been shown to be associated with durable remission, lower complication rates and reduced need for surgery and hospitalisation. (25, 26) Although mucosal healing is associated with improved outcomes, there is currently insufficient evidence to corroborate that treatment escalation to induce mucosal healing results in improved outcomes.
DRUgs AND mUCOsAl He AlINg
Not all drugs are equally effective in inducing and maintaining mucosal healing in CD. We present below a description of the common drugs used and their efficacies in the treatment of CD.
Steroids
Corticosteroids 
Colonoscopy done before and after azathioprine treatment for the Japanese cohort showed complete mucosal healing in 56%, partial mucosal healing in 19% and no healing in 25% of the patients.
Methotrexate
Methotrexate is often used as the second immunomodulator when patients stop thiopurines because of treatment failure or adverse effects. In CD, methotrexate has been shown to induce and maintain clinical remission in placebo-controlled randomised
trials. An early study has shown that 36% of CD patients achieve mucosal healing. 
The MUSIC (endoscopic MUcoSal Improvement in patients with active CD treated with certolizumab pegol) trial studied mucosal healing in patients treated with certolizumab pegol.
Patients on subcutaneous certolizumab pegol showed improvement in the endoscopic appearance of mucosal ulcers at both Weeks 10 and 54. However, complete mucosal healing was only seen in a small percentage of patients -4% and 8% at Week 10 and Week 54, respectively.
(37)
NONINvAsIve meTHODs Of As ses sINg mUCOsAl DIse Ase ACTIvIT y
In the vast majority of clinical trials, mucosal healing was assessed using colonoscopy with ileoscopy. However, endoscopy is expensive and associated with the risk of perforation. It is also difficult to justify to an asymptomatic patient the need for regular ileocolonoscopy. If the attainment of complete mucosal healing is to play a greater role in the evaluation of therapeutic response to drugs, there will be a need for noninvasive surrogate markers to quantify asymptomatic mucosal disease activity, so as to allow serial monitoring. Regular monitoring with endoscopy or noninvasive surrogate markers can then identify patients with active mucosal disease so that appropriate treatment escalation can be instituted.
Stool calprotectin
Calprotectin, a marker of inflammation, is produced by intestinal epithelial cells and leukocytes. It is a heterodimer made up of S100A8 and S100A9. Elevated levels of stool calprotectin have been found in IBD patients, and this has been shown to correlate with endoscopic disease activity measured using CDEIS and SES-CD. (38, 39) Stool calprotectin levels have also been found to decrease with anti-TNF therapy-induced endoscopic mucosal improvement. The reduction in stool calprotectin with anti-TNF therapy is found to correlate with endoscopic mucosal healing as measured by CDEIS. (40) The levels seldom normalise to that seen in normal controls, suggesting ongoing subclinical inflammatory activity even in the absence of mucosal lesions. (41) The value of stool calprotectin in predicting future clinical activity has been studied. In the STORI (infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors) study, stool calprotectin levels were higher in patients who relapsed than in patients who had sustained remission. (42) A normal stool calprotectin level had a high negative predictive value for a flare of disease activity, for up to three months. Predictive accuracy diminishes beyond three months.
In the post-surgical setting, it has been suggested that a stool calprotectin value of more than 200 mg/L is predictive of early mucosal disease recurrence. (43) Noninvasive cross-sectional imaging
Computed tomographic enterography and magnetic resonance enterography (MRE) have been used in the initial assessment of disease extent and activity in patients with CD, and as tools to follow up on disease activity after the initiation of therapy. (44) While both modalities have been found to be useful, MR imaging has an advantage in that it does not expose the patient to ionising radiation, and can therefore be used repeatedly to follow up on the resolution of disease activity. Rimola et al have described an MR activity index for CD activity that correlates well with CDEIS, and this index has been validated. (45) (46) (47) In the postoperative setting, MRE has 100% sensitivity and 89% specificity in detecting postoperative recurrence, and current evidence suggests that it may be as good as endoscopy. (48) Stool calprotectin and MRE are useful noninvasive tests that can be performed on patients who cannot or will not undergo regular endoscopy to monitor for mucosal healing. It is conceivable that algorithms will be established where a CD patient is monitored for mucosal healing using a mixture of endoscopy, stool calprotectin and MRE in the not-too-distant future.
CONClUsION
The 
